Benadryl Allergy Relief Capsules 12

Adults and children 12 years - 65 years:  One 8 mg capsule, as necessary up to three times a day.

Not recommended for adults over 65 years or children under 12 years.

It is a potent competitive histamine H1 antagonist which lacks significant anti-cholinergic effects, and has a low potential to penetrate the central nervous system.

After oral administration of a single dose of 8 mg acrivastine to adults, the onset of actions, as determined by the ability to antagonise histamine induced weals and flares in the skin, is 15 minutes. Peak effects occur at 2 hours, and although activity declines slowly thereafter, significant inhibition of histamine induced weals and flares still occur 8 hours after dose.

In patients, relief from the symptoms of allergic rhinitis is apparent within 1 hour after the systemic administration of the drug.

Also contains: Lactose, Sodium starch glycollate, Magnesium stearate, The capsule shell contains the following constituents: Gelatin, Purified water, Titanium dioxide.

Benadryl Allergy Relief is contraindicated in individuals with known hypersensitivity to acrivastine or triprolidine. Renal excretion is the principal route of elimination of acrivastine. Until specific studies have been carried out Benadryl Allergy Relief should not be given to patients with significant renal impairment.
Do not store above 30°C. Store in the original package. Keep out of the reach and sight of children.

It is usual to advise patients not to undertake tasks requiring mental alertness whilst under the influence of alcohol and other CNS depressants. Concomitant administration of acrivastine may, in some individuals, produce additional impairment.

There are no data to demonstrate an interaction between acrivastine and ketoconazole, erythromycin or grapefruit juice. However, due to known interactions between these compounds and other non-sedating antihistamines, caution is advised.

Do not exceed the stated dose.